416 related articles for article (PubMed ID: 28109264)
1. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt.
Youssef NF; El Kassas M; Farag A; Shepherd A
BMC Gastroenterol; 2017 Jan; 17(1):18. PubMed ID: 28109264
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
3. The impact of antiviral therapy for hepatitis C on the quality of life: a perspective.
Dusheiko G
Liver Int; 2017 Jan; 37 Suppl 1():7-12. PubMed ID: 28052638
[TBL] [Abstract][Full Text] [Related]
4. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.
Grotzinger KM; Younossi ZM; Giannini EG; Chen PJ; Rendas-Baum R; Theodore D
Health Qual Life Outcomes; 2016 Mar; 14():49. PubMed ID: 27004952
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL
Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
Mohamed MS; Hanafy AS; Bassiony MAA; Hussein S
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1368-1372. PubMed ID: 28953002
[TBL] [Abstract][Full Text] [Related]
8. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.
Juanbeltz R; Martínez-Baz I; San Miguel R; Goñi-Esarte S; Cabasés JM; Castilla J
PLoS One; 2018; 13(10):e0205277. PubMed ID: 30300395
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms.
Nardelli S; Riggio O; Rosati D; Gioia S; Farcomeni A; Ridola L
World J Gastroenterol; 2019 Dec; 25(48):6928-6938. PubMed ID: 31908396
[TBL] [Abstract][Full Text] [Related]
10. Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience.
Elbaz T; Elserafy M; Elakel W; Mohey MA; Abdo M; Hassany M; Mehrez M; Abouelkhair M; Yosry A; Omar A; Waked I; Elsayed MH; Mahran Z; Elshazly Y; Elgarem N; Gaballa A; Doss W; Esmat G
J Interferon Cytokine Res; 2017 Aug; 37(8):348-353. PubMed ID: 28777714
[TBL] [Abstract][Full Text] [Related]
11. Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.
Younossi Z; Henry L
Aliment Pharmacol Ther; 2015 Mar; 41(6):497-520. PubMed ID: 25616122
[TBL] [Abstract][Full Text] [Related]
12. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
Younossi ZM; Stepanova M; Sulkowski M; Foster GR; Reau N; Mangia A; Patel K; Bräu N; Roberts SK; Afdhal N; Nader F; Henry L; Hunt S
Clin Infect Dis; 2016 Oct; 63(8):1042-1048. PubMed ID: 27444413
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
Ahmed OA; Kaisar HH; Hawash N; Samir H; Shabana SST; Hassan A Fouad M; Rizk F; Abd-Elsalam S
Infect Disord Drug Targets; 2017; 17(2):95-100. PubMed ID: 28413993
[TBL] [Abstract][Full Text] [Related]
14. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.
Bonkovsky HL; Woolley JM
Hepatology; 1999 Jan; 29(1):264-70. PubMed ID: 9862876
[TBL] [Abstract][Full Text] [Related]
15. Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada.
Mason K; Dodd Z; Guyton M; Tookey P; Lettner B; Matelski J; Sockalingam S; Altenberg J; Powis J
Int J Drug Policy; 2017 Sep; 47():202-208. PubMed ID: 28619394
[TBL] [Abstract][Full Text] [Related]
16. Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies.
Siqueira FM; Ferreira VL; Borba HHL; Pontarolo R
Rev Inst Med Trop Sao Paulo; 2018 Nov; 60():e72. PubMed ID: 30462795
[TBL] [Abstract][Full Text] [Related]
17. Impact of Interferon-Based Treatment on Quality of Life and Work-Related Productivity of Korean Patients with Chronic Hepatitis C.
Ahn SH; Choe WH; Kim YJ; Heo J; Latarska-Smuga D; Kang J; Paik SW
Gut Liver; 2020 May; 14(3):368-376. PubMed ID: 31533395
[TBL] [Abstract][Full Text] [Related]
18. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C.
Amodio P; De Toni EN; Cavalletto L; Mapelli D; Bernardinello E; Del Piccolo F; Bergamelli C; Costanzo R; Bergamaschi F; Poma SZ; Chemello L; Gatta A; Perini G
J Affect Disord; 2005 Jan; 84(1):93-8. PubMed ID: 15620390
[TBL] [Abstract][Full Text] [Related]
19. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.
Elsharkawy A; Fouad R; El Akel W; El Raziky M; Hassany M; Shiha G; Said M; Motawea I; El Demerdash T; Seif S; Gaballah A; El Shazly Y; Makhlouf MA; Waked I; Abdelaziz AO; Yosry A; El Serafy M; Thursz M; Doss W; Esmat G
Aliment Pharmacol Ther; 2017 Mar; 45(5):681-687. PubMed ID: 28070899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
